ImmuLogic deal

Schering's Schering Berlin Venture Corp. subsidiary purchased 1 million shares of the biotech company at $8 per share. IMUL will receive research funding of up to $7.5 million, and milestones of up to $20 million, in addition to royalties. The Waltham, Mass., company will pay one-third of clinical development costs. ...